GFR-话题@MedSci

#GFR#

483篇内容 | 2541人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534520, encodeId=570e1534520a3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, objectType=article, longId=200981, objectId=96e62009817d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96e62009817d, replyNumber=0, likeNumber=55, createdTime=2020-09-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96e62009817d, moduleTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96e62009817d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534519, encodeId=0faa15345198c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Nat Commun：奥希替尼配合耐药信号抑制明显改善EGFR突变型肺癌的预后, objectType=article, longId=200948, objectId=f9e6200948d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9e6200948d3, replyNumber=0, likeNumber=72, createdTime=2020-09-21, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9e6200948d3, moduleTitle=Nat Commun：奥希替尼配合耐药信号抑制明显改善EGFR突变型肺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9e6200948d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534518, encodeId=6b9615345188b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Br J Cancer：EGFR—前列腺癌骨转移的稳定标志物, objectType=article, longId=200596, objectId=09ea20059668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09ea20059668, replyNumber=0, likeNumber=66, createdTime=2020-09-13, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09ea20059668, moduleTitle=Br J Cancer：EGFR—前列腺癌骨转移的稳定标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09ea20059668)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534517, encodeId=4224153451ee7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=200275, objectId=54442002e505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54442002e505, replyNumber=0, likeNumber=70, createdTime=2020-09-06, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54442002e505, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54442002e505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534516, encodeId=f7751534516c0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=肺癌新疗法——EGFR靶向降解, objectType=article, longId=199831, objectId=6fd1199831ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fd1199831ac, replyNumber=0, likeNumber=78, createdTime=2020-08-24, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fd1199831ac, moduleTitle=肺癌新疗法——EGFR靶向降解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fd1199831ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534515, encodeId=8e5c153451563, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clinica Chimica Acta：用于非小细胞肺癌患者外周血EGFR突变的超敏检测和动态监测新型液滴数字PCR检测方法的建立和验证, objectType=article, longId=199086, objectId=e4391990862a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4391990862a, replyNumber=0, likeNumber=76, createdTime=2020-08-11, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4391990862a, moduleTitle=Clinica Chimica Acta：用于非小细胞肺癌患者外周血EGFR突变的超敏检测和动态监测新型液滴数字PCR检测方法的建立和验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4391990862a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534514, encodeId=00a4153451418, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, objectType=article, longId=198499, objectId=8e7819849955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e7819849955, replyNumber=0, likeNumber=73, createdTime=2020-08-02, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e7819849955, moduleTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e7819849955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534513, encodeId=76cb1534513df, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=马学真教授：EGFR敏感突变晚期非小细胞肺癌NSCLC的全程管理要注重“线”的序贯和“面”的联合, objectType=article, longId=198315, objectId=3b9b198315c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b9b198315c9, replyNumber=0, likeNumber=51, createdTime=2020-07-31, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b9b198315c9, moduleTitle=马学真教授：EGFR敏感突变晚期非小细胞肺癌NSCLC的全程管理要注重“线”的序贯和“面”的联合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b9b198315c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534512, encodeId=14b21534512cc, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Am Soc Nephrol：白蛋白尿而非GFR的变化与2型糖尿病患者肾脏结构的早期变化有关, objectType=article, longId=195982, objectId=5643195982d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5643195982d8, replyNumber=0, likeNumber=94, createdTime=2020-06-18, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5643195982d8, moduleTitle=J Am Soc Nephrol：白蛋白尿而非GFR的变化与2型糖尿病患者肾脏结构的早期变化有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5643195982d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534511, encodeId=2111153451140, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR-TKIs药物相关口腔炎病例报告, objectType=article, longId=195842, objectId=3250195842c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3250195842c6, replyNumber=0, likeNumber=0, createdTime=2020-06-15, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3250195842c6, moduleTitle=EGFR-TKIs药物相关口腔炎病例报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3250195842c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534510, encodeId=5ddc1534510e0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%, objectType=article, longId=195492, objectId=c5e419549231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e419549231, replyNumber=0, likeNumber=86, createdTime=2020-06-10, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e419549231, moduleTitle=ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e419549231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534509, encodeId=092f1534509d4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, objectType=article, longId=195394, objectId=51fd195394e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51fd195394e1, replyNumber=0, likeNumber=24, createdTime=2020-06-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51fd195394e1, moduleTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51fd195394e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534508, encodeId=50ba1534508cd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet respir med：Tepotinib联合吉非替尼治疗EGFR-Met突变型非小细胞肺癌, objectType=article, longId=195184, objectId=ebcd19518488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebcd19518488, replyNumber=0, likeNumber=93, createdTime=2020-06-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebcd19518488, moduleTitle=Lancet respir med：Tepotinib联合吉非替尼治疗EGFR-Met突变型非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebcd19518488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534507, encodeId=5edf153450e30, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, objectType=article, longId=195114, objectId=ab2419511413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2419511413, replyNumber=0, likeNumber=82, createdTime=2020-06-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2419511413, moduleTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab2419511413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534506, encodeId=cd171534506b7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=马锐教授：EGFR罕见突变治疗风云录, objectType=article, longId=194168, objectId=82841941689c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82841941689c, replyNumber=0, likeNumber=98, createdTime=2020-05-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82841941689c, moduleTitle=马锐教授：EGFR罕见突变治疗风云录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82841941689c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534505, encodeId=16901534505f6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Blood：EGFR依赖性的DNA修复促进造血再生, objectType=article, longId=194125, objectId=7c66194125c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c66194125c5, replyNumber=0, likeNumber=83, createdTime=2020-05-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c66194125c5, moduleTitle=Blood：EGFR依赖性的DNA修复促进造血再生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c66194125c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534504, encodeId=5f651534504c5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=全球第二个三代EGFR靶向新药阿美替尼上市, objectType=article, longId=193964, objectId=6d391939641c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d391939641c, replyNumber=0, likeNumber=79, createdTime=2020-05-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d391939641c, moduleTitle=全球第二个三代EGFR靶向新药阿美替尼上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d391939641c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534503, encodeId=536a15345033d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=26, createdTime=2020-05-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534502, encodeId=6d59153450222, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, objectType=article, longId=193181, objectId=fa86193181f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa86193181f6, replyNumber=0, likeNumber=68, createdTime=2020-05-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa86193181f6, moduleTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa86193181f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534501, encodeId=938c1534501d0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, objectType=article, longId=193179, objectId=833e1931e9c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=833e1931e9c2, replyNumber=0, likeNumber=76, createdTime=2020-05-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=833e1931e9c2, moduleTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=833e1931e9c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益

2020-09-22

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

Nat Commun：奥希替尼配合耐药信号抑制明显改善EGFR突变型肺癌的预后

2020-09-21

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

Br J Cancer：EGFR—前列腺癌骨转移的稳定标志物

2020-09-13

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2020-09-06

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

肺癌新疗法——EGFR靶向降解

2020-08-24

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

Clinica Chimica Acta：用于非小细胞肺癌患者外周血EGFR突变的超敏检测和动态监测新型液滴数字PCR检测方法的建立和验证

2020-08-11

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析

2020-08-02

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

马学真教授：EGFR敏感突变晚期非小细胞肺癌NSCLC的全程管理要注重“线”的序贯和“面”的联合

2020-07-31

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

J Am Soc Nephrol：白蛋白尿而非GFR的变化与2型糖尿病患者肾脏结构的早期变化有关

2020-06-18

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

EGFR-TKIs药物相关口腔炎病例报告

2020-06-15

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

ASCO 2020丨奥希替尼实力不容小觑！EGFRm非小细胞肺癌的2年DFS率可达89%

2020-06-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌

2020-06-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet respir med：Tepotinib联合吉非替尼治疗EGFR-Met突变型非小细胞肺癌

2020-06-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌

2020-06-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

马锐教授：EGFR罕见突变治疗风云录

2020-05-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Blood：EGFR依赖性的DNA修复促进造血再生

2020-05-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

全球第二个三代EGFR靶向新药阿美替尼上市

2020-05-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2020-05-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%

2020-05-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现

2020-05-01

科室
- - 订阅+
  - 更多科室
工具
服务